William F. Trager

Affiliations: 
1967-1972 Pharmacy University of California, San Francisco, San Francisco, CA 
 1972-2009 University of Washington, Seattle, Seattle, WA 
Area:
Biochemistry
Website:
https://sop.washington.edu/william-f-trager-ph-d-remembrance/
Google:
"William Frank Trager"
Bio:

(1937 - 2009)

Mean distance: (not calculated yet)
 

Parents

Sign in to add mentor
Alain C. Huitric grad student 1965 University of Washington
 (NMR analysis of substituted cyclohexylamine and nitrocyclohexanes; strong coupling and solvent effects in conformational analysis of mobile six-membered ring compounds.)
Arnold Heyworth Beckett post-doc 1967 University of London
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Trnka MJ, Doneanu CE, Trager WF. (2006) Photoaffinity labeling of P450Cam by an imidazole-tethered benzophenone probe. Archives of Biochemistry and Biophysics. 445: 95-107
Suzuki H, Kneller MB, Rock DA, et al. (2004) Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors. Archives of Biochemistry and Biophysics. 429: 1-15
Nelson SD, Trager WF. (2003) The use of deuterium isotope effects to probe the active site properties, mechanism of cytochrome P450-catalyzed reactions, and mechanisms of metabolically dependent toxicity. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 31: 1481-98
Neal JM, Kunze KL, Levy RH, et al. (2003) Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 31: 1043-8
Yao C, Kunze KL, Trager WF, et al. (2003) Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 31: 565-71
Sachdeo RC, Sachdeo SK, Levy RH, et al. (2002) Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia. 43: 691-6
Suzuki H, Kneller MB, Haining RL, et al. (2002) (+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 30: 235-9
Yao C, Kunze KL, Kharasch ED, et al. (2001) Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. Clinical Pharmacology and Therapeutics. 70: 415-24
Henne KR, Fisher MB, Iyer KR, et al. (2001) Active site characteristics of CYP4B1 probed with aromatic ligands. Biochemistry. 40: 8597-605
He M, Rettie AE, Neal J, et al. (2001) Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 29: 701-11
See more...